Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Bristol-Myers ... BMY an edge in the market. The focus now shifts to Cobenfy's launch performance and how it will fare against competitor data expected in the fourth quarter of 2024.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q4 CY2024, with sales up 7.5% year on year to $12.34 ...

HIDDEN under the shadow of an Ikea superstore, this so-called ‘caravan city’ reveals the stark reality of life for those without a home to even furnish. Freezing in below-zero ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks.

A higher fair value than the current market price drives investors' interest ... For the current quarter, Bristol Myers is expected to post earnings of $1.46 per share, indicating a change of ...

“So when I put into my very helpful DeepSeek, what famous picture ... quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

S&P 500 futures pared an early gain fueled by Treasury Secretary Scott Bessent’s comment that the Trump administration is ...

Through the third quarter ... picture in a meaningful way. To me, oncology represents a hugely important new area for Lilly, and one that is ripe for disruption given the size of the addressable ...